Diego Signorelli

List of Publications by Citations

Source: https://exaly.com/author-pdf/242821/diego-signorelli-publications-by-citations.pdf
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51 papers	1,209 citations	21 h-index	34 g-index
52 ext. papers	1,605 ext. citations	4.5 avg, IF	4.09 L-index

#	Paper	IF	Citations
51	Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. *Clinical Cancer Research*, **2019**, 25, 989-999	12.9	213
50	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. *ESMO Open*, **2019**, 4, e000457	6	93
49	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. *Cancer Treatment Reviews*, **2019**, 75, 39-51	14.4	85
48	Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. *Cancers*, **2020**, 12,	6.6	73
47	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer **2019**, 7, 316		56
46	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. *Clinical Cancer Research*, **2019**, 25, 2166-2173	12.9	47
45	Cognitive impairment and chemotherapy: a brief overview. *Critical Reviews in Oncology/Hematology* , **2017**, 118, 7-14	7	44
44	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. *Cancers*, **2019**, 11,	6.6	39
43	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. *Lung Cancer*, **2019**, 132, 72-78	5.9	34
42	Treatment of lung large cell neuroendocrine carcinoma. *Tumor Biology*, **2016**, 37, 7047-57	2.9	34
41	Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. *European Journal of Cancer*, **2019**, 123, 72-80	7.5	34
40	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥50. *Cancer Immunology, Immunotherapy*, **2020**, 69, 2209-2221	7.4	32
39	Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. *Lung Cancer*, **2019**, 137, 38-42	5.9	29
38	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. *BioMed Research International*, **2019**, 2019, 9056417	3	28
37	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. *Translational Lung Cancer Research*, **2016**, 5, 563-578	4.4	28
36	Concomitant rearrangement and mutation in non-small cell lung cancer patients: a literature review of 100 cases. *Oncotarget*, **2017**, 8, 59889-59900	3.3	26
35	Diagnosis and management of typical and atypical lung carcinoids. *Critical Reviews in Oncology/Hematology*, **2016**, 100, 167-76	7	26

34	Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. *Lung Cancer*, **2018**, 115, 135-142	5.9	23
33	Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. *BMC Musculoskeletal Disorders*, **2010**, 11, 34	2.8	22
32	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. *Lung Cancer*, **2020**, 140, 59-64	5.9	22
31	Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. *Translational Lung Cancer Research*, **2020**, 9, 1533-1542	4.4	21
30	Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort. *Journal of Thoracic Disease*, **2019**, 11, 4972-4981	2.6	15
29	Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. *Clinical Lung Cancer*, **2019**, 20, e413-e417	4.9	15
28	Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis. *PLoS ONE*, **2016**, 11, e0157751	3.7	14
27	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. *Targeted Oncology*, **2018**, 13, 795-800	5	14
26	Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. *Tumor Biology*, **2016**, 37, 12991-13003	2.9	12
25	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. *Lung Cancer*, **2019**, 132, 17-23	5.9	11
24	Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. *Journal of Clinical Medicine*, **2020**, 9,	5.1	11
23	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. *Lung Cancer*, **2021**, 152, 165-173	5.9	11
22	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. *Cancers*, **2019**, 11,	6.6	10
21	Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%. *Journal of Immunotherapy*, **2020**, 43, 299-306	5	10
20	Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation. *Oncology*, **2015**, 89, 227-34	3.6	9
19	Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?. *Tumori*, **2016**, 102, 18-30	1.7	8
18	Post-progression outcomes of NSCLC patients with PD-L1 expression ≥50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. *European Journal of Cancer*, **2021**, 148, 24-35	7.5	8
17	Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem. *Current Drug Targets*, **2017**, 18, 341-362	3	7

16	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. *Future Oncology*, **2019**, 15, 2743-2757	3.6	5
15	Cardiac Metastasis from Renal Cell Carcinoma Successfully Treated with Pazopanib: Impact of TKIsS Antiangiogenic Activity. *Tumori*, **2014**, 100, e298-e300	1.7	5
14	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.. *JCO Precision Oncology*, **2020**, 4, 829-840	3.6	5
13	Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. *Clinical Lung Cancer*, **2021**, 22, e180-e192	4.9	5
12	LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments. *Journal of Thoracic Oncology*, **2021**, 16, 1298-1311	8.9	5
11	Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIsS antiangiogenic activity. *Tumori*, **2014**, 100, e298-300	1.7	5
10	Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer. *Tumori*, **2019**, 105, NP57-NP62	1.7	4
9	DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. *Clinical Lung Cancer*, **2020**, 21, e337-e348	4.9	4
8	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. *Translational Lung Cancer Research*, **2020**, 9, 617-628	4.4	3
7	The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. *Clinical Lung Cancer*, **2019**, 20, e652-e660	4.9	2
6	Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of ≥50%		1
5	mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. *ESMO Open*, **2020**, 5, e000748	6	1
4	SMO mutations confer poor prognosis in malignant pleural mesothelioma. *Translational Lung Cancer Research*, **2020**, 9, 1940-1951	4.4	0
3	Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. *Translational Lung Cancer Research*, **2021**, 10, 2955-2969	4.4	0
2	mutations confer poor prognosis in malignant pleural mesothelioma. *Translational Lung Cancer Research*, **2020**, 9, 1940-1951	4.4	
1	Facing the First-line in Metastatic Non-small-cell Lung Cancer Immunotherapy and Chemotherapy. *European Oncology and Haematology*, **2020**, 16, 39	0.1	